Skip to content
Home
About us
Team
Investments
Investor Relations
ESG
News
Meet us
align-justify
Menu
Home
About us
Team
Investments
Investor Relations
ESG
News
Meet us
user-group
INVESTOR ACCESS
Search
Search
Close this search box.
apps
Menu
Home
About us
Team
Investments
Investor Relations
ESG
News
Meet us
Home
/
Venture Capital
/
MRM Health Reports Preclinical...
Venture Capital
MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis
6 June 2022
Download
Press Release
Download
Related News
Buyout
Other news
April 5, 2024
Biobest signs agreement with Aqua Capital and GIC to acquire Biotrop in Brazil
arrow-up-right
Venture Capital
Other news
February 20, 2024
World’s first clinical stage bi-manual ophthalmology robot successfully completes retinal surgery case
arrow-up-right
Venture Capital
Other news
February 20, 2024
MRM Health Initiates Clinical Research in Parkinson’s Disease
arrow-up-right
